Kwok Ying Chan

Get full text access Log in, subscribe or purchase for full access. References 1. The Lancet Global Health The landscape for rare diseases in 2024 Lancet Glob Health. 2024; 12:e341 2. Boycott, KM ∙ Rath, A ∙ Chong, JX ∙ et al. International cooperation to enable the diagnosis of all rare genetic diseases Am J Hum Genet. 2017; 100:695-705 3. Uhlenbusch, N ∙ Swaydan, J ∙ Höller, A ∙ et al.

To the Editor We read with interest the article by Abel et al1 that examined shared care after allogeneic hematopoietic cell transplant, which underscored the early quality-of-life (QOL) benefits of shared care. However, there are several methodological limitations warranting further discussion. First, the intervention was not standardized.

To the Editor We were greatly intrigued by the VOICE randomized clinical trial by Krebs et al,1 which evaluated integrated pain team (IPT) compared with pharmacist collaborative management (PCM) among patients taking long-term opioid therapy. Although we appreciate their efforts, some of the methodologic limitations are worth discussing. First, response rates differed greatly from those assumed for power calculations.